Kornimate/medical-research-clean huggingface dataset:
eating with eosinophilic esophagitis (eoe)

Conditions: Eosinophilic Esophagitis (EoE)

Summary: is there a difference in the eating process for patients with active eosinophilic esophagitis (eoe) and those with inactive disease?

eosinophilic esophagitis (eoe) patients develop adapted eating behaviors to prevent symptoms. these patients tend to cut their food small, chew extensively, take copious liquids with meals, and avoid foods that cause symptoms. no studies to date have directly evaluated these eating behaviors in patients with eoe with observation. furthermore, none of the investigators' current metrics for patient symptom assessment visually evaluate the eating process nor are they compared before and after treatment. as a result, it is unclear if a patient's subjective perception of their eating difficulties and improvement matches with objective measures.

Eligibility criteria:
inclusion criteria: * 18 years of age and older * patients suspected to have eosinophilic esophagitis * patients being treated for eoe with ppi or a steriod * eoe patients that are in remission by having less than 22 on the eesai questionnaire * controls, patients that do not have eoe or other swallowing issues exclusion criteria: * clinical evidence of infectious process potentially contributing to dysphagia (candidiasis, cmv,herpes) * other cause of dysphagia identified at endoscopy (reflux esophagitis, stricture, web, ring, achalasia, esophageal neoplasm) * eoe patients that do not eat sandwiches or feel they could not eat a sandwich.

Keywords: eoe dysphagia
observational, prospective, cohort study of mpox infection in brazil (netpox)

Conditions: Monkeypox; MPOX

Summary: the study is a prospective cohort that evaluates the clinical and immune-metabolic variables that may be linked to the risk and severity of the infection or even hospitalization or death in patients infected with the mpox virus in brazil. the expectation is to include at least 80 patients over six months, with a follow-up of 90 days from inclusion, through contact via decentralized visits.


Eligibility criteria:
inclusion criteria: * men and women aged ≥ 18 years with confirmed mpox infection. (laboratory-confirmed monkeypox infection is defined as determined by pcr, culture, or antigen test obtained from a sample collected from blood, oropharynx, anal or skin lesion within 4 days of randomization) exclusion criteria: * inability to provide informed consent; * patient who, judging by the study team, does not have a condition for decentralized follow-up
resting-state functional mri in patients with optic neuritis for anticipation of recovery

Conditions: Neuritis

Summary: when patients arrive in the waiting room of the mri department, patients will be given the briefing note explaining the purpose of the study and how it is going. during the consultation, the radiologist will check the inclusion and non-inclusion criteria, and will take the time to answer all of the patient's questions about the study. if the patient agrees to participate in the research, the investigating doctor will obtain his consent. the mri examination will be performed on a 3t multi-parametric mri. compared to the standard protocol, patients will benefit from an additional sequence of f-mri, called resting state, and performed before injection of gadolinium contrast agent. a consultation with an ophthalmologist will also be carried out the same day, at the adolphe de rothschild foundation. during this visit, an oct examination (optical coherence tomography), a visual field as well as the measurement of visual acuity will be carried out, in accordance with the treatment usually practiced at the adolphe de rothschild foundation. the subjects of the control group who agreed to participate will benefit from an mri examination which will include, in addition to the sequences planned for these patients according to their indications, the two non-injected sequences which will be performed on patients with suspected no. the possible existence of visual problems in the subjects of the control group will also be asked to them by interrogation. no eye exams or follow-up visits are planned, and control group participation will end after the mri scan. patients with no will be seen in consultation by an ophthalmologist during a follow-up visit approximately 6 months after diagnosis. during this consultation, an oct, a visual field and the measurement of visual acuity will be performed. this visit and the examinations carried out correspond to the usual care of patients suffering from no and followed at the adolphe de rothschild foundation hospital.


Eligibility criteria:
inclusion criteria: * patients over 18 years of age * clinical suspicion of optic neuritis * benefiting from an mri for exploration of optic neuritis * affiliate or beneficiary of a social security scheme * having received informed information about the study and having given their express consent to participate in the study exclusion criteria: * contraindication to absolute or relative mri (in particular, pregnant or breastfeeding women) * history of amblyopia * any pre-existing pathology leading to a decrease in vision (e.g. retinitis pigmentosa, amd, etc.) * patient benefiting from a legal protection measure
effects of anti-vegf targeted drugs on patients' blood pressure and endothelial function

Conditions: Cardiac Toxicity; VEGF; Endothelial Dysfunction

Summary: explore the effects of anti-vegf targeted drugs on blood pressure and endothelial function in cancer patients.

thirty tumor patients with anti-vegf drugs were selected. demographic information and clinical information of all patients were collected before chemotherapy. ambulatory blood pressure monitoring and endothelial function measurement (pwv, endopat) were performed. ambulatory blood pressure and pwv were reviewed at 2 weeks and 1 month. and endopat, to evaluate the effects of anti-vegf drugs on blood pressure and endothelial function in cancer patients.

Eligibility criteria:
inclusion criteria: * tumor patients using anti-vegf drugs exclusion criteria: * hypertension, coronary heart disease, valvular heart disease, cardiomyopathy and other organic heart diseases, exclude liver and kidney failure, severe cerebrovascular disease, chronic obstructive pulmonary disease, rheumatic immune system disease

Keywords: cardiac safety anti-vegf drugs endothelial dysfunction
role of bone in knee osteoarthritis (oa)

Conditions: Osteoarthritis, Knee

Summary: the purpose of the study is to investigate protein and gene expression among damaged knee tissues. we will perform mri's on subjects prior to total knee replacement to identify the location of bone marrow lesions. connective tissues including tendon, ligament, and meniscus specimens normally discarded from total joint replacements will be used for live cell harvest, and protein and gene expression analyses of tissue or cultured cells.

background and significance: although the presence of bone marrow lesions (bml) on mri is strongly associated with osteoarthritis (oa) progression and pain in some studies, the mechanism for this relation and the underlying pathology is not well established. the lack of knowledge on what these lesions constitute hampers their clinical utility both with regards to measurement and targeting for therapeutic intervention. our preliminary data has localized specific changes in bone mineralization, remodeling and defects within bml features that are adjacent to the subchondral plate. bmls appear to be sclerotic compared to unaffected regions; however, the mineral density in these lesions is reduced and may render this area to be mechanically compromised, and thus susceptible to attrition. limited histological analysis of bmls reveal thrombi, diffuse fibrinoid necrosis and hyperplasia of blood vessel walls - all indicative of infarction-like pathology. the aim of this research proposal is to create more specific targets and improve our understanding of the pathology in bmls. specific aim 1: - to collect tissue to evaluate protein and gene expression of these tissues and cultured cells.

Eligibility criteria:
inclusion criteria: * subjects having primary knee replacement surgery with 1 participating surgeon at nebh (principal investigator) exclusion criteria: * subjects having a revision knee replacement instead of a primary knee replacement * contraindications for mri * pregnancy

Keywords: bone marrow lesion bml arthroplasty replacement knee discarded tissue
probiotics as adjunct to non surgical periodontal therapy for pregnant women oral health

Conditions: Periodontal Diseases

Summary: the aim of the present study is to evaluate the use of probiotics in domiciliary oral hygiene procedures in pregnant women. patients consenting to participate to the study will undergo periodontal evaluation at the baseline (t0). then, professional dental hygiene will be performed. patients will be randomly assigned to: * trial group: home oral application of biorepair peribioma toothpaste + biorepair peribioma mousse twice a day * control group: home oral application of biorepair peribioma toothpaste patients will be evaluated after 1 month (t1), 3 (t2) and 6 (t3) months.

the aim of the present study is to evaluate the use of probiotics in domiciliary oral hygiene procedures in pregnant women. patients consenting to participate to the study will undergo periodontal evaluation at the baseline (t0). then, professional dental hygiene will be performed. patients will be randomly assigned to: * trial group: home oral application of biorepair peribioma toothpaste + biorepair peribioma mousse twice a day * control group: home oral application of biorepair peribioma toothpaste patients will be evaluated after 1 month (t1), 3 (t2) and 6 (t3) months, the following indexes will be assessed: probing pocket depth, bleeding on probing (percentage), clinical attachment loss, gingival recession, plaque control record, modified gingival index, papillary marginal gingival index.

Eligibility criteria:
inclusion criteria: * women at the 4th month of pregnancy exclusion criteria: * presence of cardiac pacemaker * neurological and psychiatric diseases * patients taking bisphosphonates during the previous 12 months from the beginning of the study * patients undergoing anticancer therapy. * patients with poor compliance.

Keywords: pregnancy
gastroesophageal reflux disease prospective registry

Conditions: GERD

Summary: the purpose of this registry is to evaluate information to determine which operations and treatments for gastroesophageal reflux disease or similar diseases of the stomach, esophagus or digestive tract are providing the most benefit including the long-term effects of treatment (or no treatment) and the progression of the disease over time.

all patients in this registry will have a diagnosis of gastroesophageal reflux disease or a similar disease of the stomach, esophagus or digestive tract. each patient undergoing anti-reflux surgery will be asked to participate in the registry to gather preoperative, intraoperative and postoperative outcomes. the data collected from the registry will be used to assess the outcome of various treatments, both standard and new: some specific areas of interest include the long-term effects of treatment (or no treatment), the progression of the disease over time, and the overall length of survival of the patient.

Eligibility criteria:
inclusion criteria: - any patient undergoing anti-reflux surgery exclusion criteria: - none
choice sets for advance directives

Conditions: End Stage Renal Disease

Summary: there is a large gap between the care seriously ill patients want and the care they receive. advance directives (ads) offer an opportunity for patients to express specific end-of-life preferences to avoid unwanted care. as promising as ads may be for improving the quality of care near the end of life, rates of ad completion remain low and previous efforts to encourage their completion have had limited success. principles of behavioral economics, such as the effects of defaults and other framing effects, may offer a novel approach to bridge the gap in end-of-life care. the goal of this study is to test whether the framing effect of expanding choice sets can increase the completion of and specification of choices within advance directives.

this study has been designed as two sequential randomized trials to test two separate expanded choice set interventions, with the second randomization enrollment being contingent on results from the first. all enrolled subjects will be asked if they would like to complete an advance directive and will have been randomized to receive either an expanded answer choice set or a standard answer choice, as described in detail elsewhere. only those subjects who express a desire to complete an advance directive from both arms will then be randomized again in a stratified fashion to receive either a standard advance directive or one with an expanded choice set for the decisions regarding life-sustaining therapy, as described in detail elsewhere.

Eligibility criteria:
inclusion criteria: * age 18 or older * proficient in english * chronic hemodialysis for minimum 90 days * does not currently have a living will exclusion criteria: * blindness * cognitive impairment that prohibits subject's provision of informed consent

Keywords: end stage renal disease hemodialysis dialysis
lateral versus posterior quadratus lumborum block in the pediatric patients undergoing orchiopexy

Conditions: Pain

Summary: there is a complex innervation of the testis and spermatic canal, and many different regional analgesia methods can be used for pain occurring during and after undescended testicular surgery. quadratus lumborum block (qlb) can be count as the one of the primary method to manage the pain. in this study, our primary aim will be to compare the effects of lateral and posterior qlb application on perioperative and postoperative pain and analgesic use in pediatric patients who will undergo unilateral elective undescended testicular surgery. our secondary aim will be to compare patient and family satisfaction and complications.

american society of anesthesiologists physical status classification system (asa) class i-iii, aged 6 month-12 years old children undergoing unilateral elective orchiopexy with general anesthesia will be recruited, after the informed consent will be obtained from the parents of the patients, in this triple blind randomized controlled trial. after the premedication with ketamine and midazolam will be performed, the patient will be brought to the operation room. after the induction with thiopental 5mg/kg, fentanyl 1mcg/kg, rocuronium 0.6mg/kg, patients will be intubated. the maintenance of the anesthesia will be provided with sevoflurane. subsequently, before the surgery, the patients will be randomized and separated into 2 groups. the investigators will apply the lateral qlb to the first group and posterior qlb to the other group. 0.4 ml/kg %0.25 bupivacaine will be used as a local anesthetic agent in both group. in the peroperative period, if the additional analgesia will necessary, remifentanyl 0.1mcg/kg/min will be started, and dosage will be adjusted according to heart rate and blood pressure. if the blood pressure or heart rate will increase more than 20% from the preoperative basal value will be defined as the need for the analgesia. in the postoperative period, all cohort will be assessed by a blinded investigator at the 10,20,30th minutes, 1,2nd hours in the recovery room, 6th hour in the surgical ward, face, legs, activity, cry, consolability scale (flacc) will be used for the pain evaluation. 16th and 24th hours will be monitored by the telephone visit from the parents, the pain will be evaluated with the wong-baker faces pain rating scale due to the same-day surgery concept.

Eligibility criteria:
inclusion criteria: * asa physical status i-iii * undergoing elective unilateral orchiopexy exclusion criteria: * not giving a consent * regional anesthesia contraindications * asa physical status iv * need to postoperative icu care * laparoscopic orchiopexy

Keywords: quadratus lumborum block pediatric patient orchiopexy pain regional anesthesia
phenotypisation of sleep pattern in hypertensive patients with non dipper pattern

Conditions: Hypertension; Sleep Disorder

Summary: high blood pressure is the most common modifiable risk factor for cardiovascular diseases (cv). the large interindividual variability in clinical expression of the disease and response to treatment, however, makes the management of the hypertensive patient complex.therefore, identifying phenotypes of hypertensive patients associated with a specific cv outcome or who tend to respond/not respond to treatment is of paramount importance for improving cv prevention. it has been shown that the phenotype of hypertensive patient with poor control of nighttime blood pressure values, especially when associated with a "non-dipper" profile, was associated with an increased risk of developing cv and cerebrovascular complications. the non-dipper profile and nocturnal hypertension are caused by several factors including excessive salt intake and dysautonomia. however, they are also inevitably influenced by sleep duration and the presence of sleep disorders: obstructive sleep apnea (osa), but also insomnia and periodic movements of the lower limbs,such as those frequently seen in restless legs syndrome, are among the the main determinants related to altered nighttime pressure pattern. however, such disturbances are not systematically assessed during the performance of monitoring 24h pressor and their impact in the outcome of the hypertensive patient is unknown. the primary objective of this study is to phenotype non-dipper patients with or without nocturnal hypertension to determine the prevalence of sleep disorders such as sleep apnea syndrome, insomnia, and restless legs syndrome (rls) (osa diagnosed considering ahi\>5 events/hour, insomnia and rls according to icsd 3 criteria) and correlate the presence of various sleep disorders with cardiac organ damage, vascular, and renal damage mediated by hypertension.


Eligibility criteria:
inclusion criteria: * \>18 years old; * arterial hypertension defined as: a) office systolic bp ≥140 mmhg and/or diastolic bp ≥90 mmhg and either 24-hour ambulatory systolic bp ≥130 mmhg and/or diastolic bp ≥80 mmhg or b) the presence of antihypertensive treatment; * non-dipper pattern at 24-hour bp monitoring (confirmed on repeated abpm including one performed within 3 months prior to enrolment and one after enrolment, both on the same antihypertensive treatment, if any), defined as a nocturnal decrease systolic and/or in diastolic bp values \<10% compared to the corresponding daytime values; * signed written informed consent; exclusion criteria: * shift workers * atrial fibrillation/flutter; * pregnancy and lactation; * terminal malignant disease, life expectancy \<6 months; * limb amputation; * dementia.
reducing use of sleep medications assisted by a digital insomnia intervention

Conditions: Insomnia

Summary: chronic insomnia is one of the most common health problems among veterans and significantly impacts their health, function, and quality of life. sedative-hypnotic medications are the most common treatment despite mixed effectiveness and are associated with numerous risks that can further impact veteran function. an intervention combining evidence-based interventions for deprescribing sedative-hypnotics and behavioral interventions for insomnia (e.g., cognitive behavioral therapy for insomnia \[cbt-i\]) can help to optimize sleep and functional outcomes for veterans with a desire to reduce or stop using these medications. furthermore, by delivering these interventions through an easy to use and highly accessible digital platform can provide additional benefits to veterans, especially those with limited time and access to engage in traditional in-person interventions. the clinician operated assistive sleep technology (coast) is an efficient, scalable, and adaptable platform that can help providers to reach more veterans and provide evidence-based care that translates to improved health and function. aim 1: to assess the feasibility of recruiting veterans with chronic sedative-hypnotic use to participate in a 12-week combined deprescribing and cbt-i intervention, delivered through the coast digital platform. aim 2: to assess veteran acceptability and usability of the coast platform. aim 3: to assess change in veteran sleep, sedative-hypnotic use, and function pre- to post-intervention.


Eligibility criteria:
inclusion criteria: * a veteran receiving care at va pittsburgh healthcare system * active sedative-hypnotic medication use \>14 days/month for \>=3 months * a desire to reduce or stop using sedative-hypnotic medications * access to a mobile device with internet exclusion criteria: * a disorder that would impair participation (e.g., cancer, uncontrolled pain, severe depression) * a disorder that can be exacerbated by changes in sleep (e.g., seizure disorder, bipolar i disorder) * high risk of suicide * an active substance use disorder in past 6 months

Keywords: insomnia veterans hypnotics and sedatives deprescribing cognitive behavioral therapy for insomnia telemedicine mobile applications
split-face study: cosmetic botulinum toxin type a injection under electromyography-guidance versus conventional palpation technique

Conditions: Glabellar Frown Lines; Rhytides; Wrinkle; Facial Expression

Summary: the aim of this study was to compare between the conventional palpation method of botulinum toxin type a injection and the electromyography-guided method using clinical parameters and electromyography analysis.

the study was conducted on 15 healthy-looking female subjects with visible glabellar rhytids when frowning. all participants were recruited from the outpatient clinic of dermatology department, main university hospital, faculty of medicine, alexandria university. the mean age was 46.27 ± 6.31 with a range from 33 to 59 years. all 15 subjects completed the study. each subject provided a right and left corrugator supercilii muscles to the study. each muscle was divided into a body and a tail, each part injected separately (n=60). neurotoxin injection into the corrugator body and tail by palpation method on one side and under emg-guidance on the other. photographs were taken both at rest, and while frowning at each visit: pre-operatively, after 2 weeks and after 3 months. clinical grading according to static and dynamic merz glabellar frown line scales and emg analysis was done at each visit: pre-operatively, after 2 weeks and after 3 months.

Eligibility criteria:
inclusion criteria: * consent. * patients within age range of 25 - 60 years. * visible corrugator muscle rhytids when frowning by examination. exclusion criteria: * patients with no, or minimal wrinkles on the studied area. * previous use of botulinum toxin in the previous 6 months. * patients on regular or very occasional antispasmodics. * patients with any neuromuscular disorders, infections or skin problems at the injection site. * patients with any known neurological disease. * patients who undergone surgery involving the glabellar area.

Keywords: botulinum toxin emg-guided botulimun toxin injection cosmetic botulinum toxin glabellar merz scale